Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

997
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
997
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

370
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
370
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

Leukemia & lymphoma·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Blood·2026
Same author

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation.

Blood neoplasia·2026
Same author

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Blood advances·2026
Same author

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Internal medicine journal·2026

Related Experiment Video

Updated: Aug 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

Acute myeloid leukaemia.

Courtney D DiNardo1, Harry P Erba2, Sylvie D Freeman3

  • 1Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA.

Lancet (London, England)
|April 17, 2023
PubMed
Summary
This summary is machine-generated.

Recent advances in acute myeloid leukemia (AML) treatment include updated classifications and improved prognostic tools, especially measurable residual disease (MRD) monitoring. New therapies offer better outcomes for newly diagnosed and relapsed AML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

193
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

Related Experiment Videos

Last Updated: Aug 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

193
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) treatment is rapidly advancing.
  • Understanding AML biology has improved prognostication and risk assessment.
  • Measurable residual disease (MRD) is now key in longitudinal risk assessments.

Purpose of the Study:

  • To review recent advancements in AML treatment.
  • To highlight updated classifications and prognostic tools.
  • To discuss evolving therapeutic options for AML.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of updated classification systems (WHO, ICC).
  • Evaluation of European LeukemiaNet recommendations for MRD and response assessment.

Main Results:

  • Significant evolution in AML treatment over the past 5 years.
  • Improved outcomes for both intensive and non-intensive chemotherapy regimens.
  • Development of novel targeted therapies for relapsed AML.

Conclusions:

  • AML treatment landscape has transformed, improving patient outcomes.
  • Updated classifications and MRD assessments refine patient management.
  • Expanded therapeutic options enhance the treatment armamentarium for AML.